Clinical trial
Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected…
NCT00352911 · VGX Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00352911 |
|---|---|
| Title | Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects |
| Official title | A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects |
| Lead sponsor | VGX Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | VGX-410 (Mifepristone), Placebo for VGX-410 (Mifepristone) |
| Enrollment | 19 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jul 17, 2006 |
| Last update posted | Mar 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: